All

Basel, Switzerland – 18 Dec, 2024, Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer…

We are pleased to share that Stromal Therapeutics have published groundbreaking research in Cell, shedding light on a critical interplay between fibroblasts and the local…

One of our preclinical companies is currently looking for an experienced biopharma entrepreneurial-minded CEO. The company specializes in engineering next-generation biologics to rebalance the immune…

Basel, Switzerland and Cambridge, MA – 9 Dec, 2024, Cimeio Therapeutics announced that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa…

MetaLead Therapeutics AG, a spin-out from the University of Zurich, is pioneering the field of metal-related diseases by focusing on novel therapeutic approaches for conditions…

Basel, Switzerland – 12 Nov, 2024, The BaseLaunch portfolio company Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and…

Synendos AG, a BaseLaunch portfolio company, has been awarded a prestigious grant under the Start-Up Innovation Project (SIP) scheme by Innosuisse. This highly competitive initiative…

Transitioning from early- to late-stage development is a pivotal phase for any biotech startup. This journey, often laden with both opportunities and challenges, requires a…

Basel, Switzerland – 2 Oct, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced yesterday…

MT-act spun out from the Institute of Human Genetics and CNRS in Montpellier, leverages recent advances in understanding cytoskeleton stiffness and its influence on age-related…